X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
TrueBinding will use Horizon’s cGMP-compliant CHOSOURCE™ platform for the development and commercialization of multiple biotherapeutic products for applications in immuno-oncology and other disease areas with great unmet medical need.
Lead Product(s): Chinese Hamster Ovary K1 cell
Therapeutic Area: Oncology Product Name: Chosource
Highest Development Status: Discovery PlatformProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: TrueBinding
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 29, 2020
Details:
The micro-RNA was identified as suitable for further development based on favorable pharmacokinetic results as well as pharmacodynamic data at the molecular level.
Lead Product(s): miRNA-125b
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
